Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shuhei Hige
Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy
Acta Hepatologica Japonica
Hepatology
A Randomized Trial of 24 Versus 48 Weeks of Peginterferon Α-2a in Patients Infected With Chronic Hepatitis C Virus Genotype 2 or Low Viral Load Genotype 1: A Multicenter National Study in Japan
Hepatology International
Hepatology
Related publications
Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection
Eastern Mediterranean Health Journal
Medicine
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
Gastroenterology
Hepatology
Gastroenterology
Prediction of Anemia in Triple Therapy With Peginterferon ^|^alpha;-2b, Ribavirin, and Telaprevir for Patients With Chronic Hepatitis C From the Viewpoint of Renal Function
Acta Hepatologica Japonica
Hepatology
Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C
Archives of Internal Medicine
Cost-Effectiveness Analysis of Treatment With Peginterferon-Alfa-2a Versus Peginterferon-Alfa-2b for Patients With Chronic Hepatitis C Under the Public Payer Perspective in Brazil
Cost Effectiveness and Resource Allocation
Health Policy
Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response
Hepatology
Medicine
Hepatology
PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C
Internal Medicine
Internal Medicine
Medicine
Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial
The Lancet
Medicine
